Avanir vet Kei­th Katkin takes charge at Urovant; Te­va un­loads as­sets while up­load­ing new CEO

⇨ Roivant Sci­ences has added an­oth­er sea­soned biotech ex­ec to its sta­ble of CEOs. The um­brel­la group an­nounced this morn­ing that Kei­th Katkin, the long­time CEO at Avanir up to its sale to Ot­su­ka, is tak­ing the CEO’s job at Urovant. The start­up vant is fo­cused on uro­log­i­cal con­di­tions.

⇨ Most com­pa­nies wait for a new CEO to step in be­fore they re­or­ga­nize, but Te­va nev­er had the time. The trou­bled Is­raeli bio­phar­ma com­pa­ny has sold off the last of its women health as­sets, rais­ing about $1.4 bil­lion as Kare Schultz pre­pares to take the helm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER